{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:51:12Z","timestamp":1792036272346,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment landscape for Multiple Sclerosis (MS) has increased significantly over the past few decades, thanks to the introduction of disease-modifying therapies (DMTs). Fingolimod, siponimod, ozanimod, and ponesimod belong to the newer generation of oral DMTs categorized as sphingosine 1-phosphate receptor modulators (S1PRMs). Because of their mechanism of action, they may increase the risk of lymphopenia, which could influence the therapeutic management of people with MS. The aim of this study was to describe and compare the reporting frequency of lymphopenia related to four S1PRMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individual case safety reports (ICSRs) were retrieved from the European spontaneous reporting system database (EudraVigilance) from January 1st, 2022, to December 31st, 2023. The reporting odds ratios (RORs) were computed to compare the reporting probability of lymphopenia between a S1PRM versus each other.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We retrieved 4017 ICSRs, of which 521 (13%) reported lymphopenia associated with fingolimod (53.3%), siponimod (38.4%), ozanimod (5.4%), and ponesimod (2.1%). The most common reporting source was the healthcare professional (94.2%), and more than half of the ICSRs (62.6%) reported serious lymphopenia. Fingolimod was associated with a lower reporting frequency of lymphopenia compared to siponimod. Both siponimod and fingolimod were associated with a higher reporting frequency of lymphopenia compared to ozanimod; siponimod also had a higher reporting probability in comparison with ponesimod.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The most relevant clinical implication of the disproportionality analysis is to increase the awareness of the risk of lymphopenia related to these drugs, thus supporting proactive monitoring and optimizing treatment strategies for people with MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-025-00725-6","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:58:17Z","timestamp":1744149497000},"page":"775-788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data"],"prefix":"10.1007","volume":"77","author":[{"given":"Nunzia","family":"Balzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fraenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Di Giulio Cesare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Moreggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia Teresa","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liberata","family":"Sportiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"725_CR1","doi-asserted-by":"publisher","unstructured":"Joshua AM, Tiwari A, Kumari N, Pai S. Multiple sclerosis. Physiother Adult Neurol Cond. 2022;563\u2013601. https:\/\/doi.org\/10.1007\/978-981-19-0209-3_9.","DOI":"10.1007\/978-981-19-0209-3_9"},{"key":"725_CR2","unstructured":"Tafti D, Ehsan M, Xixis KL. Multiple Sclerosis. StatPearls 2022."},{"key":"725_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0041-4","volume":"41","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Prim. 2018;41:4:1\u201327. https:\/\/doi.org\/10.1038\/s41572-018-0041-4.","journal-title":"Nat Rev Dis Prim 2018"},{"key":"725_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/S41582-021-00519-3","volume":"17","author":"N Makhani","year":"2021","unstructured":"Makhani N, Tremlett H. The multiple sclerosis prodrome. Nat Rev Neurol. 2021;17:515. https:\/\/doi.org\/10.1038\/S41582-021-00519-3.","journal-title":"Nat Rev Neurol"},{"key":"725_CR5","unstructured":"Number of people with MS. | Atlas of MS n.d. https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms (accessed May 14, 2024)."},{"key":"725_CR6","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123\u201336. https:\/\/doi.org\/10.1177\/1352458517694432.","journal-title":"Mult Scler"},{"key":"725_CR7","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/S00415-019-09489-5\/FIGURES\/3","volume":"268","author":"H Inojosa","year":"2021","unstructured":"Inojosa H, Proschmann U, Akg\u00fcn K, Ziemssen T. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. J Neurol. 2021;268:1210\u201321. https:\/\/doi.org\/10.1007\/S00415-019-09489-5\/FIGURES\/3.","journal-title":"J Neurol"},{"key":"725_CR8","doi-asserted-by":"publisher","first-page":"824926","DOI":"10.3389\/FNEUR.2022.824926\/BIBTEX","volume":"13","author":"JH Yang","year":"2022","unstructured":"Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic advances in multiple sclerosis. Front Neurol. 2022;13:824926. https:\/\/doi.org\/10.3389\/FNEUR.2022.824926\/BIBTEX.","journal-title":"Front Neurol"},{"key":"725_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/AJHP\/ZXAD247","volume":"81","author":"A Edinger","year":"2024","unstructured":"Edinger A, Habibi M. The evolution of multiple sclerosis disease-modifying therapies: an update for pharmacists. Am J Health Syst Pharm. 2024;81:37\u201355. https:\/\/doi.org\/10.1093\/AJHP\/ZXAD247.","journal-title":"Am J Health Syst Pharm"},{"key":"725_CR10","unstructured":"European Medicine Agency. Gilenya, INN-fingolimod -. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS n.d."},{"key":"725_CR11","unstructured":"European Medicine Agency. INN-siponimod; Mayzent - ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS n.d."},{"key":"725_CR12","unstructured":"European Medicine Agency. Zeposia; ozanimod - ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS n.d."},{"key":"725_CR13","unstructured":"European Medicine Agency. INN-ponesimod; Ponvory - ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS n.d."},{"key":"725_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","volume":"24","author":"L Dumitrescu","year":"2023","unstructured":"Dumitrescu L, Papathanasiou A, Coclitu C, Garjani A, Evangelou N, Constantinescu CS, et al. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opin Pharmacother. 2023;24:495. https:\/\/doi.org\/10.1080\/14656566.2023.2178898.","journal-title":"Expert Opin Pharmacother"},{"key":"725_CR15","unstructured":"NOVARTIS. Summary of Risk management plan for Mayzent\u2122 (Siponimod) 2022."},{"key":"725_CR16","unstructured":"Janssen. EU Safety Risk Managment plan - Ponvory (Ponesimod). 2024."},{"key":"725_CR17","unstructured":"Squibb B. EU Safety Risk Managment plan - ZEPOSIA (OZANIMOD). 2024."},{"key":"725_CR18","unstructured":"NOVARTIS. EU Safety Risk Managment plan - Fingolimod. 2021."},{"key":"725_CR19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ACN3.52017","volume":"11","author":"PK Coyle","year":"2024","unstructured":"Coyle PK, Freedman MS, Cohen BA, Cree BAC, Markowitz CE. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review. Ann Clin Transl Neurol. 2024;11:842. https:\/\/doi.org\/10.1002\/ACN3.52017.","journal-title":"Ann Clin Transl Neurol"},{"key":"725_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3988\/JCN.2022.18.6.663","volume":"18","author":"SY Huh","year":"2022","unstructured":"Huh SY, Kim SH, Kim KH, Kwon YN, Kim SM, Kim SW, et al. Safety and Temporal pattern of the lymphocyte count during Fingolimod therapy in patients with multiple sclerosis: Real-World Korean experience. J Clin Neurol. 2022;18:663\u201370. https:\/\/doi.org\/10.3988\/JCN.2022.18.6.663.","journal-title":"J Clin Neurol"},{"key":"725_CR21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/13524585231225711\/SUPPL_FILE\/SJ-DOCX-3-MSJ-10.1177_13524585231225711.DOCX","volume":"30","author":"CG Gilmartin","year":"2024","unstructured":"Gilmartin CG, Hoyle N, Garjani A, Dixon T, Jos H, Paling D, et al. Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis. Mult Scler. 2024;30:600\u20134. https:\/\/doi.org\/10.1177\/13524585231225711\/SUPPL_FILE\/SJ-DOCX-3-MSJ-10.1177_13524585231225711.DOCX.","journal-title":"Mult Scler"},{"key":"725_CR22","doi-asserted-by":"publisher","first-page":"104551","DOI":"10.1016\/J.MSARD.2023.104551","volume":"71","author":"E Swallow","year":"2023","unstructured":"Swallow E, Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, et al. Comparative efficacy and safety of ozanimod and Ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison. Mult Scler Relat Disord. 2023;71:104551. https:\/\/doi.org\/10.1016\/J.MSARD.2023.104551.","journal-title":"Mult Scler Relat Disord"},{"key":"725_CR23","doi-asserted-by":"publisher","first-page":"105135","DOI":"10.1016\/J.MSARD.2023.105135","volume":"81","author":"D Caliendo","year":"2024","unstructured":"Caliendo D, Grassia MC, Carotenuto A, Petracca M, Lanzillo R, Brescia Morra V, et al. Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia. Mult Scler Relat Disord. 2024;81:105135. https:\/\/doi.org\/10.1016\/J.MSARD.2023.105135.","journal-title":"Mult Scler Relat Disord"},{"key":"725_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/S40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf. 2024;47:575. https:\/\/doi.org\/10.1007\/S40264-024-01421-9.","journal-title":"Drug Saf"},{"key":"725_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/JNNP-2015-310597","volume":"87","author":"JA Cohen","year":"2015","unstructured":"Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, et al. Long-term (up to 4.5\u2005years) treatment with Fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2015;87:468. https:\/\/doi.org\/10.1136\/JNNP-2015-310597.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"725_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/1352458513500551\/ASSET\/IMAGES\/LARGE\/10.1177_1352458513500551-FIG3.JPEG","volume":"20","author":"G Francis","year":"2014","unstructured":"Francis G, Kappos L, O\u2019Connor P, Collins W, Tang D, Mercier F, et al. Temporal profile of lymphocyte counts and relationship with infections with Fingolimod therapy. Mult Scler J. 2014;20:471\u201380. https:\/\/doi.org\/10.1177\/1352458513500551\/ASSET\/IMAGES\/LARGE\/10.1177_1352458513500551-FIG3.JPEG.","journal-title":"Mult Scler J"},{"key":"725_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of Fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545\u201356. https:\/\/doi.org\/10.1016\/S1474-4422(14)70049-3.","journal-title":"Lancet Neurol"},{"key":"725_CR28","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30475-6.","journal-title":"Lancet"},{"key":"725_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","volume":"15","author":"JA Cohen","year":"2016","unstructured":"Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:373\u201381. https:\/\/doi.org\/10.1016\/S1474-4422(16)00018-1.","journal-title":"Lancet Neurol"},{"key":"725_CR30","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18:1009\u201320. https:\/\/doi.org\/10.1016\/S1474-4422(19)30239-X.","journal-title":"Lancet Neurol"},{"key":"725_CR31","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/JAMANEUROL.2021.0405","volume":"78","author":"L Kappos","year":"2021","unstructured":"Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdov\u00e1 EK, Hennessy B, et al. Ponesimod compared with Teriflunomide in patients with relapsing multiple sclerosis in the Active-Comparator phase 3 OPTIMUM study: A randomized clinical trial. JAMA Neurol. 2021;78:558\u201367. https:\/\/doi.org\/10.1001\/JAMANEUROL.2021.0405.","journal-title":"JAMA Neurol"},{"key":"725_CR32","doi-asserted-by":"publisher","unstructured":"Cinar P, Piri B, Konuskan B, Anlar B, Ozakbas S. Narrative review based on Fingolimod therapy in pediatric MS. SAGE Open Med. 2023;11. https:\/\/doi.org\/10.1177\/20503121231171996.","DOI":"10.1177\/20503121231171996"},{"key":"725_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/ENE.13506","volume":"25","author":"H Houzen","year":"2018","unstructured":"Houzen H, Kondo K, Horiuchi K, Niino M. Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in Northern Japan. Eur J Neurol. 2018;25:334\u20139. https:\/\/doi.org\/10.1111\/ENE.13506.","journal-title":"Eur J Neurol"},{"key":"725_CR34","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler. 2020;26:1816\u201321. https:\/\/doi.org\/10.1177\/1352458520970841.","journal-title":"Mult Scler"},{"key":"725_CR35","doi-asserted-by":"publisher","first-page":"1397291","DOI":"10.3389\/FPHAR.2024.1397291\/BIBTEX","volume":"15","author":"L Sportiello","year":"2024","unstructured":"Sportiello L, Capuano A. Sex and gender differences and pharmacovigilance: a knot still to be untied. Front Pharmacol. 2024;15:1397291. https:\/\/doi.org\/10.3389\/FPHAR.2024.1397291\/BIBTEX.","journal-title":"Front Pharmacol"},{"key":"725_CR36","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/BPH.12362","volume":"171","author":"F Franconi","year":"2014","unstructured":"Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014;171:580. https:\/\/doi.org\/10.1111\/BPH.12362.","journal-title":"Br J Pharmacol"},{"key":"725_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","volume":"2","author":"M Rademaker","year":"2001","unstructured":"Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol. 2001;2:349\u201351. https:\/\/doi.org\/10.2165\/00128071-200102060-00001.","journal-title":"Am J Clin Dermatol"},{"key":"725_CR38","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1212\/WNL.0000000000001049","volume":"83","author":"C Warnke","year":"2014","unstructured":"Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, et al. Initial lymphocyte count and low BMI May affect fingolimod-induced lymphopenia. Neurology. 2014;83:2153\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000001049.","journal-title":"Neurology"},{"key":"725_CR39","doi-asserted-by":"publisher","first-page":"1386527","DOI":"10.3389\/FNEUR.2024.1386527\/BIBTEX","volume":"15","author":"C Scavone","year":"2024","unstructured":"Scavone C, Liguori V, Adungba OJ, Cesare DDG, Sullo MG, Andreone V, et al. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series. Front Neurol. 2024;15:1386527. https:\/\/doi.org\/10.3389\/FNEUR.2024.1386527\/BIBTEX.","journal-title":"Front Neurol"},{"key":"725_CR40","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/PH16111566\/S1","volume":"16","author":"L Sportiello","year":"2023","unstructured":"Sportiello L, Di Napoli R, Balzano N, Mascolo A, Ruggiero R, Di Costanzo L, et al. Disease-Modifying therapies (DMTs) in pregnant and lactating women with multiple sclerosis: analysis of Real-World data from eudravigilance database. Pharmaceuticals. 2023;16:1566. https:\/\/doi.org\/10.3390\/PH16111566\/S1.","journal-title":"Pharmaceuticals"},{"key":"725_CR41","doi-asserted-by":"publisher","first-page":"1383910","DOI":"10.3389\/FNEUR.2024.1383910\/BIBTEX","volume":"15","author":"C Scavone","year":"2024","unstructured":"Scavone C, Anatriello A, Baccari I, Cantone A, Di Giulio Cesare D, Bernardi FF, et al. Comparison of injective related reactions following ofatumumab and Ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system. Front Neurol. 2024;15:1383910. https:\/\/doi.org\/10.3389\/FNEUR.2024.1383910\/BIBTEX.","journal-title":"Front Neurol"},{"key":"725_CR42","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/S40265-021-01528-8","volume":"81","author":"T P\u00e9rez-Jeldres","year":"2021","unstructured":"P\u00e9rez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting Sphingosine-1-Phosphate signaling in Immune-Mediated diseases: beyond multiple sclerosis. Drugs. 2021;81:985\u20131002. https:\/\/doi.org\/10.1007\/S40265-021-01528-8.","journal-title":"Drugs"},{"key":"725_CR43","doi-asserted-by":"publisher","unstructured":"Hla T, Brinkmann V. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology. 2011;76. https:\/\/doi.org\/10.1212\/WNL.0B013E31820D5EC1.","DOI":"10.1212\/WNL.0B013E31820D5EC1"},{"key":"725_CR44","doi-asserted-by":"publisher","unstructured":"Liu R, Du S, Zhao L, Jain S, Sahay K, Rizvanov A, et al. Autoreactive lymphocytes in multiple sclerosis: pathogenesis and treatment target. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/FIMMU.2022.996469.","DOI":"10.3389\/FIMMU.2022.996469"},{"key":"725_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2217\/CER-2019-0169","volume":"9","author":"E Swallow","year":"2020","unstructured":"Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, et al. Comparative safety and efficacy of ozanimod versus Fingolimod for relapsing multiple sclerosis. J Comp Eff Res. 2020;9:275\u201385. https:\/\/doi.org\/10.2217\/CER-2019-0169.","journal-title":"J Comp Eff Res"},{"key":"725_CR46","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2147\/PPA.S221882","volume":"16","author":"S Sabsabi","year":"2022","unstructured":"Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M. Clinical evaluation of Siponimod for the treatment of secondary progressive multiple sclerosis: pathophysiology, efficacy, safety, patient acceptability and adherence. Patient Prefer Adherence. 2022;16:1307. https:\/\/doi.org\/10.2147\/PPA.S221882.","journal-title":"Patient Prefer Adherence"},{"key":"725_CR47","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ACN3.52017","volume":"11","author":"PK Coyle","year":"2024","unstructured":"Coyle PK, Freedman MS, Cohen BA, Cree BAC, Markowitz CE. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review. Ann Clin Transl Neurol. 2024;11:842\u201355. https:\/\/doi.org\/10.1002\/ACN3.52017.","journal-title":"Ann Clin Transl Neurol"},{"key":"725_CR48","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/S40268-023-00434-6","volume":"23","author":"M Vali\u0161","year":"2023","unstructured":"Vali\u0161 M, Achiron A, Hartung HP, Mare\u0161 J, Tich\u00e1 V, \u0160toura\u010d P, et al. The benefits and risks of switching from Fingolimod to Siponimod for the treatment of Relapsing\u2013Remitting and secondary progressive multiple sclerosis. Drugs R D. 2023;23:331. https:\/\/doi.org\/10.1007\/S40268-023-00434-6.","journal-title":"Drugs R D"},{"key":"725_CR49","doi-asserted-by":"publisher","unstructured":"Fischer S, Proschmann U, Akg\u00fcn K, Ziemssen T. Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects. Cells 2021, Vol 10, Page 3177. 2021;10:3177. https:\/\/doi.org\/10.3390\/CELLS10113177","DOI":"10.3390\/CELLS10113177"},{"key":"725_CR50","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/S40262-023-01308-5","volume":"62","author":"TM Kruger","year":"2023","unstructured":"Kruger TM, Valenzuela B, Thompson CD, Ouwerkerk-Mahadevan S, Ruixo JJP. Clinical pharmacokinetics of Ponesimod, a selective S1P1 receptor modulator, in the treatment of multiple sclerosis. Clin Pharmacokinet. 2023;62:1533\u201350. https:\/\/doi.org\/10.1007\/S40262-023-01308-5.","journal-title":"Clin Pharmacokinet"},{"key":"725_CR51","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1080\/14656566.2020.1799977","volume":"21","author":"E Baldin","year":"2020","unstructured":"Baldin E, Lugaresi A. Ponesimod for the treatment of relapsing multiple sclerosis. Expert Opin Pharmacother. 2020;21:1955\u201364. https:\/\/doi.org\/10.1080\/14656566.2020.1799977.","journal-title":"Expert Opin Pharmacother"},{"key":"725_CR52","doi-asserted-by":"publisher","first-page":"13839","DOI":"10.1074\/JBC.M311743200","volume":"279","author":"MG Sanna","year":"2004","unstructured":"Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004;279:13839\u201348. https:\/\/doi.org\/10.1074\/JBC.M311743200.","journal-title":"J Biol Chem"},{"key":"725_CR53","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1007\/S10072-021-05546-Y","volume":"42","author":"M Sparaco","year":"2021","unstructured":"Sparaco M, Miele G, Bonavita S. Severe lymphopenia switching from Fingolimod to Siponimod. Neurol Sci. 2021;42:4837\u20138. https:\/\/doi.org\/10.1007\/S10072-021-05546-Y.","journal-title":"Neurol Sci"},{"key":"725_CR54","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1212\/WNL.0000000000002654","volume":"86","author":"TV Gyang","year":"2016","unstructured":"Gyang TV, Hamel J, Goodman AD, Gross RA, Samkoff L. Fingolimod-associated PML in a patient with prior immunosuppression. Neurology. 2016;86:1843. https:\/\/doi.org\/10.1212\/WNL.0000000000002654.","journal-title":"Neurology"},{"key":"725_CR55","doi-asserted-by":"publisher","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","volume":"90","author":"JR Berger","year":"2018","unstructured":"Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, et al. Progressive multifocal leukoencephalopathy after Fingolimod treatment. Neurology. 2018;90:e1815. https:\/\/doi.org\/10.1212\/WNL.0000000000005529.","journal-title":"Neurology"},{"key":"725_CR56","doi-asserted-by":"publisher","unstructured":"Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S, et al. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2021;360. https:\/\/doi.org\/10.1016\/J.JNEUROIM.2021.577721.","DOI":"10.1016\/J.JNEUROIM.2021.577721"},{"key":"725_CR57","doi-asserted-by":"publisher","first-page":"611711","DOI":"10.3389\/FIMMU.2021.611711\/BIBTEX","volume":"12","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Ma CL, Gu ZC, Dong Y, Lv Y, Zhong MK. Incidence and risk of infection associated with Fingolimod in patients with multiple sclerosis: A systematic review and Meta-Analysis of 8,448 patients from 12 randomized controlled trials. Front Immunol. 2021;12:611711. https:\/\/doi.org\/10.3389\/FIMMU.2021.611711\/BIBTEX.","journal-title":"Front Immunol"},{"key":"725_CR58","doi-asserted-by":"publisher","first-page":"1376494","DOI":"10.3389\/FPHAR.2024.1376494\/FULL","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang X, Yan Y, Liu S, Wang Z, Feng X. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2024;15:1376494. https:\/\/doi.org\/10.3389\/FPHAR.2024.1376494\/FULL.","journal-title":"Front Pharmacol"},{"key":"725_CR59","doi-asserted-by":"publisher","unstructured":"Henschke A, Desborough J, Parkinson A, Brunoro C, Fanning V, Lueck C, et al. Personalizing medicine and technologies to address the experiences and needs of people with multiple sclerosis. J Pers Med. 2021;11. https:\/\/doi.org\/10.3390\/JPM11080791.","DOI":"10.3390\/JPM11080791"},{"key":"725_CR60","doi-asserted-by":"publisher","unstructured":"Stamatellos VP, Rigas A, Stamoula E, Lallas A, Papadopoulou A, Papazisis G. S1P receptor modulators in multiple sclerosis: detecting a potential skin cancer safety signal. Mult Scler Relat Disord. 2022;59. https:\/\/doi.org\/10.1016\/J.MSARD.2022.103681.","DOI":"10.1016\/J.MSARD.2022.103681"},{"key":"725_CR61","doi-asserted-by":"publisher","unstructured":"Ye J, Lee PP. B cell receptor signaling strength modulates cancer immunity. J Clin Invest. 2022;132. https:\/\/doi.org\/10.1172\/JCI157665.","DOI":"10.1172\/JCI157665"},{"key":"725_CR62","doi-asserted-by":"publisher","unstructured":"Zinzi A, Gaio M, Liguori V, Ruggiero R, Tesorone M, Rossi F, et al. Safety monitoring of mRNA COVID-19 vaccines in children aged 5 to 11 years by using eudravigilance pharmacovigilance database: the CoVaxChild study. Vaccines. 2023;11. https:\/\/doi.org\/10.3390\/VACCINES11020401.","DOI":"10.3390\/VACCINES11020401"},{"key":"725_CR63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/17512433.2023.2211262","volume":"16","author":"R Ruggiero","year":"2023","unstructured":"Ruggiero R, Di Napoli R, Balzano N, Ruggiero D, Riccardi C, Anatriello A, et al. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management. Expert Rev Clin Pharmacol. 2023;16:423\u201334. https:\/\/doi.org\/10.1080\/17512433.2023.2211262.","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00725-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00725-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00725-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T09:10:50Z","timestamp":1747041050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00725-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00725-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}